Opioid use may worsen gastric retention Higher prevalence of recent opioid use in the high RGC group Suggests an additive effect on gastric motility No difference in indication or duration of therapy Whether patients used GLP-1 RAs for diabetes or weight loss did not affect risk Duration of therapy was not a significant predictor Interpretation Withholding 7.5 days higher risk of retained gastric contents Fasting 21.3 hours strongest predictor of high RGC These thresholds optimize sensitivity and specificity for detecting risk
The FDA prescribing information for semaglutide and tirzepatide lists fatigue as an adverse reaction occurring in clinical studies, with incidence rates typically ranging from 5-11% depending on the specific product and dosage
The only way to find out is to talk to your insurance provider directly
On the other hand, some studies have reported no significant differences in GR activity in MASH children (Desai et al
The protein concentrations were determined using a DC Protein Assay Kit, (Bio-Rad, United States), as described previously[21-25]
[DOI] [PMC free article] [PubMed] [Google Scholar] 4.Ciavarella D., Campobasso A., Conte E., Burlon G., Guida L., Montaruli G., Cassano M., Laurenziello M., Illuzzi G., Tepedino M
-1775582746855.png&w=3840&q=75)
